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S-Petasin is the main sesquiterpene of Petasites formosanus, a traditional folk medicine used to treat hypertension, tumors
and asthma in Taiwan. The aim of the present study was to investigate its inhibitory eﬀects on phosphodiesterase (PDE)
1–5, and on ovalbumin (OVA)-induced airway hyperresponsiveness (AHR) in a murine model of allergic asthma. S-Petasin
concentration-dependently inhibited PDE3 and PDE4 activities with 50% inhibitory concentrations (IC50) of 25.5, and 17.5μM,
respectively. According to the Lineweaver-Burk analysis, S-petasin competitively inhibited PDE3 and PDE4 activities with
respective dissociation constants for inhibitor binding (Ki) of 25.3 and 18.1μM, respectively. Both IC50 and Ki values for PDE3
were signiﬁcantly greater than those for PDE4. S-Petasin (10–30μmol/kg, administered subcutaneously (s.c.)) dose-dependently
and signiﬁcantly attenuated the enhanced pause (Penh) value induced by methacholine (MCh) in sensitized and challenged mice. It
alsosigniﬁcantlysuppressedtheincreasesintotalinﬂammatorycells,lymphocytes,neutrophils,eosinophilsandlevelsofcytokines,
including interleukin (IL)-2, IL-4 and IL-5, tumor necrosis factor (TNF)-α and interferon (IFN)-γ in bronchoalveolar lavage ﬂuid
(BALF) of these mice. In addition, S-petasin (10–30μmol/kg, s.c.) dose-dependently and signiﬁcantly attenuated total and OVA-
speciﬁc immunoglobulin E (IgE) levels in the serum and BALF, and enhanced the IgG2a level in serum of these mice. The PDE4H
value of S-petasin was >300μM; therefore, its PDE4H/PDE4L value was calculated to be >17. In conclusion, the present results for
S-petasin at least partially explain why Petasites formosanus is used as a folk medicine to treat asthma in Taiwan.
1.Introduction
Recently, Ze 339, an extract of Petasites hybridus L. (Com-
positae), was approved by the Swiss government agency,
Swissmedic, as an anti-allergic drug (Tesalin; Zeller AG,
Romanshorn, Switzerland) to treat seasonal allergic rhinitis.
In a study by Schapowal [1], the clinical eﬀects of Ze
339 were similar to those of cetirizine, an antagonist of
histamine receptor subtype 1, although Ze 339 was reported
to elicit no skin test reactivity induced by diﬀerent stimuli
[2]. The plant is used as a therapeutic spasmolytic agent
for gastrointestinal tract spasms [3] and asthmatic attacks
[4] in Europe. Four sesquiterpenoid substances, petasin,
isopetasin, S-petasin and S-isopetasin, were isolated from
the plant [5], and petasin was reported to have the highest
spasmolytic activity [6]. These four sesquiterpenes are also
present in the aerial part of Petasites formosanus Kitamura,
a traditional folk medicine used to treat hypertension,
tumors and asthma in Taiwan [7], and S-petasin is the
most abundant [8]. S-Petasin, with an IC50 of <10μM,
was proven to be the most potent in relaxing guinea pig
tracheaprecontractedbyhistamine,carbachol(CCh),KClor
leukotriene (LT) D4, although S-isopetasin (IC50 ∼ = 10μM)
has a similar relaxing potency on CCh and KCl, but almost
no eﬀect on histamine and LT D4 [9]. Recently, we reported
that S-isopetasin has bronchodilatory eﬀects on obstructive2 Evidence-Based Complementary and Alternative Medicine
airwayhyperresponsiveness(AHR)viaitsantimuscarinicM3
antagonism [10]. S-Petasin, but not S-isopetasin, inhibited
cAMP-phosphodiesterase (PDE) activity [11].
PDEs are classiﬁed according to their primary pro-
tein and complementary (c)DNA sequences, co-factors
and substrate speciﬁcities, and pharmacological roles. It is
now known that PDEs comprise of at least 11 distinct
enzyme families that hydrolyze cAMP and/or cGMP [12].
PDE1–5 isozymes, which are calcium/calmodulin-depend-
ent (PDE1), cGMP-stimulated (PDE2), cGMP-inhibited
(PDE3), cAMP-speciﬁc (PDE4) and cGMP-speciﬁc (PDE5),
have been found to be present in the canine trachea [13],
guinea pig lung [14] and human bronchi [15]. PDE3 and
PDE4 were identiﬁed in the guinea pig airway [16], but
other isozymes might also be present. Rolipram, a prototype
PDE4selectiveinhibitor,hashigh(PDE4H)andlo w(PDE4 L)
aﬃnities for PDE4, respectively. In general, it is believed that
inhibition of PDE4H is associated with an adverse response,
such as nausea, vomiting and gastric hypersecretion, and
inhibition of PDE4L is associated with anti-inﬂammatory
and bronchodilating eﬀects. Therefore, the therapeutic ratio
of selective PDE4 inhibitors for use in treating asthma and
chronic obstructive pulmonary disease (COPD) is deﬁned as
the PDE4H/PDE4L ratio [17, 18]
Rolipram or zardaverin (dual PDE3/4 inhibitor), but not
siguazodan (a selective PDE3 inhibitor), markedly inhibited
aerosol ovalbumin (OVA)-induced broncho-constriction in
conscious guinea pigs, and inhibited OVA-induced contrac-
tions of isolated guinea pig trachea [19]. Underwood et
al. [19] suggested that the combined inhibition of both
PDE3 and PDE4 isozymes acts in an additive or synergistic
manner to inhibit brochospasms in the guinea pig, although
selective PDE3 or PDE4 inhibitors are ineﬀective against the
exogenous histamine- and LTD4-induced contractions. The
aim of present study was to investigate whether S-petasin
inhibits both PDE3 and PDE4 isozymes, and whether it has
the potential for use in treating asthma or COPD.
2. Methods
2.1. Reagents and Animals. S-Petasin (Figure 1)w a si s o -
lated as previously described [8] from the aerial parts of
Petasites formosanus Kitamura, and identiﬁed by spectral
methods, including infrared (IR), mass spectroscopy (MS),
one-dimensional (1D)- and 2D-nuclear magnetic resonance
(NMR) spectroscopic techniques. The purity of S-petasin
was>99%.Itsopticalrotationvaluewas[α]
25
D +58.0
◦ (c1.0,
MeOH). OVA, methacholine (MCh), polyethyleneimine, (2-
hydroxypropyl)-β-cyclodextrin (HPβCD), calmodulin, dim-
ethylsulfoxide (DMSO), Trizma HCl, bis(2-hydroxyeth-
yl)aminotris(hydroxymethyl)methane (Bis-Tris), benzami-
dine,phenylmethanesulfonylﬂuoride(PMSF),polyethylene-
imine, d,l-dithiothreitol, ethylenediaminetetraacetic acid
(EDTA), bovine serum albumin (BSA), adenosine 3 ,5 
cyclic monophosphate (cAMP), guanosine 3 ,5  cyclic
monophosphate (cGMP), calmodulin, Dowex resin, Cro-
talus atrox snake venom, xylazine and ketamine were
purchased from Sigma Chemical (St. Louis, MO, USA).
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Figure 1: Chemical structure of S-petasin (mol. wt., 334), isolated
from Petasites formosanus Kitamura.
(EHNA), milrinone, rolipram, 4-(3-butoxy-4-methoxyben-
zyl)-2-imidazolidinone (Ro 20-1724), and zaprinast were
purchased from Biomol (Plymouth Meeting, PA, USA). Fre-
und’s adjuvant (Mycobacterium butyricum) was purchased
from Pierce Biotechnology (Rockford, IL, USA). Mouse T
helper (Th)1/Th2 cytokine CBA kits, and mouse IgE and
IgG2a ELISA sets were purchased from Pharmingen (San
Diego, CA, USA). Polyethyleneglycol (PEG) 400 and ethyl
alcohol were purchased from Merck (Darmstadt, Germany).
[2,8-3H]-cAMP, [8-3H]-cGMP, and [methyl-3H]-rolipram
were purchased from Amersham Pharmacia Biotech (Buck-
inghamshire, UK). Other reagents, such as CaCl2,M g C l 2
and NaCl, were of analytical grade. S-Petasin and vinpocetin
were dissolved in a mixture of ethyl alcohol and DMSO
(1:1). EHNA and Ro 20-1724 were dissolved in ethyl
alcohol. Milrinone and zaprinast were dissolved in DMSO.
Other drugs were dissolved in distilled water. The ﬁnal
concentration of ethyl alcohol or DMSO was ≤0.5%, and
did not signiﬁcantly aﬀect the activities of PDE isozymes or
tracheal contractions.
MaleHartleyguineapigs(500–600g)andfemaleBABL/c
mice at 8–12 weeks were obtained from the Animal Center
of the National Science Council (Taipei, Taiwan). The
animals were housed in ordinary cages at 22 ± 1◦Cw i t ha
humidity of 50–60% under a constant 12/12-h light/dark
cycle and provided with food and water ad libitum.U n d e r
a protocol approved by the Animal Care and Use Committee
ofTaipeiMedicalUniversity,thefollowinginvivoandinvitro
experiments were performed.
2.2. Inhibition on PDE Activities and the Lineweaver-Burk
Analysis. Activities of PDE1–5, partially separated from
guinea pig lungs and hearts according to the method
described by Ko et al. [20], were measured with a two-
step procedure according to the method of Thompson and
Appleman [21],usingcAMPwith[3H]-cAMPorcGMPwith
[3H]-cGMP as substrates. The enzyme pμreparation (25μL)
was incubated for 30min at 37
◦C in a total assay volume of
100L containing 50mM Tris-HCl (pH 7.4), 3mM MgCl2,
1mM dithiothreitol, 0.05% BSA, 1μMc A M Pw i t h0 . 2μCi
[3H]-cAMP as a substrate alone or in the presence of 0.1
units calmodulin with 10μMC a C l 2 or 5μMc G M P ,a n d
1μMc G M Pw i t h0 . 2μCi [3H]-cGMP as another substrate
alone or in the presence of 0.1 units calmodulin with
10μMC a C l 2. In tests of enzyme inhibition, the reaction
mixture contained 10μL of vehicle or inhibitors, at various
concentrations of S-petasin or selective PDE1–5 inhibitors,Evidence-Based Complementary and Alternative Medicine 3
such as vinpocetin [22], EHNA [23], milrinone [24], Ro 20-
1724[25]andzaprinast[26],asreferencedrugs.Thereagents
and homogenate were mixed on ice, and the reaction was
initiated by transferring the mixture to a water bath at 37
◦C.
Following a 30-min incubation, the reaction was stopped
by transferring the reaction vessel to a bath of boiling
water for 3min. After cooling on ice, 20μLo fa1 m g / m L
solution of C. atrox snake venom was added to the reaction
mixture, and the mixture was incubated at 37
◦C for 10min.
Unreacted [3H]-cAMP or [3H]-cGMP was removed by the
addition of 500μL of a 1-in-1 Tris-HCl (40mM) buﬀer
suspension of Dowex resin (1 × 8-200) with incubation on
ice for 30min. Each tube was then centrifuged for 2min at
3700g,and150μLofthe supernatantwasremovedforliquid
scintillation counting. Less than 10% of the tritiated cyclic
nucleotide was hydrolyzed in this assay. The total protein
in each fraction used was assayed according to the method
described by Bradford [27]. The PDE activities are shown as
nmol/mg/min in the Lineweaver-Burk analysis.
2.3. Determination of PDE4H Values. When the above-
described guinea pigs were sacriﬁced, the whole brains were
removed and homogenized with a glass/Teﬂon homogenizer
(Glas-Col, Terre Haute, IN, USA) in 10 volumes of cold
medium (pH 6.5) containing 20mM Bis-Tris, 2mM ben-
zamidine, 2mM EDTA, 50mM sodium chloride, 0.1mM
PMSF and 1mM dithiothreitol. At 4◦C, the homogenate
was centrifuged at 170g for 5min to remove connective
tissues and blood vessels. The suspended homogenate was
then re-centrifuged at 40000g for 30min to separate the
cytosolic and particulate portions. The particulate portion
was re-suspended in a suspension at a concentration of
400mg/mL (wet weight/volume), after washing three times
with homogenizing buﬀer. The particulate portion mainly
consisted of cell membranes. The binding ability of S-petasin
(3–300μM) or Ro 20-1724 (1–10,000nM), a reference
drug, to high-aﬃnity rolipram binding sites (HARBSs) of
the membranes was determined by replacing 2nM [3H]-
rolipram in a reaction buﬀer at 30
◦C for 1h, according
to the method described by previous investigators [28, 29]
and modiﬁed by us. Brieﬂy, the reaction buﬀer consisted
of 50mM Tris-HCl and 5mM MgCl2 (pH 7.5). The total
volume of the reaction mixture was 25μL, consisting of
10μL of particulate suspension, 10μLo f[ 3H]-rolipram and
5μLo fS-petasin or Ro 20-1724. After 1h, the reaction was
terminated by moving the reaction vessel into crushed ice.
Then the reaction mixture was transferred onto Whatman
GF/B glass-ﬁber ﬁlters, which were soaked in a 0.3%
polyethyleneimine solution in a mini-funnel. The reaction
mixture was ﬁltered by centrifuging at 90g for 10s, and
the ﬁltrate was collected into a 1.5mL Eppendorf tube
with a top adapted to the outlet of the mini-funnel. The
ﬁlters were washed with 300μLo fr e a c t i o nb u ﬀer three
times each in the same way, and transferred into 2mL of
cocktail for radiation counting (total binding) using a β-
scintillation counter (Beckman, Fullerton, CA, USA). Non-
speciﬁc binding, which was deﬁned in the presence of
10μM Ro 20-1724, was subtracted from the total binding
to yield the speciﬁc binding. The eﬀective concentration
(EC50)v a l u e so fS-petasin and Ro 20-1724, at which a half of
[3H]-rolipram bound onto HARBSs of cell membranes was
displaced, were deﬁned as the PDE4H values, and these were
related to any adverse eﬀects, such as nausea, vomiting and
gastric hypersecretion [30].
2.4. Airway Hyperresponsiveness In Vivo. Ten female BABL/c
mice in each group were sensitized by an intraperitoneal
(i.p.) injection of 20μgo fO V Ae m u l s i ﬁ e di n2 . 2 5 m g
aluminum hydroxide gel in a total volume of 100μLo nd a y s
0 and 14. The mice were challenged via the airway by 1%
OVA in saline for 30min on Days 28, 29 and 30 by ultrasonic
nebulization. Six weeks after the last of three primary OVA
challenges, the mice were exposed to 1% OVA for 30min
by nebulization as a secondary challenge [31]. AHR was
assessed on Day 74 (48h after 1% OVA provocation) in
each group. Each group of mice was subcutaneously (s.c.)
injected with vehicle (control), or 30–100μmol/kg of S-
p e t a s i n2 hb e f o r ea n d6a n d2 4 ha f t e rO V Ap r o v o c a t i o n .
For comparison, sham-treated mice were sensitized but chal-
lenged with saline instead of 1% OVA (non-challenged). The
vehicle, a mixture of alcohol:DMSO:30% HPβCD:saline
(0.5: 0.5:1:8 , v/v), or S-petasin was injected at a volume
of 0.01mL/g of body weight. AHR was measured in unre-
strained animals by barometric plethysmography [32] using
a whole-body plethysmograph (WBP) and analyzed using
software of Life Science Suite P3 Analysis Modules (Gould,
LDS Test and Measurement LLC, Valley View, OH, USA).
ThemicewereplacedintothemainchamberoftheWBP,and
the baseline enhanced pause (Penh) value was determined.
Then the mice were nebulized ﬁrst with phosphate-buﬀered
saline (PBS), and subsequently with increasing doses (6.25–
50mg/mL) of MCh for 3min for each nebulization, followed
by readings of breathing parameters for 3min after each
nebulization with determination of Penh values. Twenty-
four hours after the Penh determination, these mice were
anesthetized with pentobarbital (50mg/kg, i.p.), and lavaged
vi aatra c h e a lt u b ewi t hP B S( 1× 1.0mL, 37
◦C). After lavage,
blood was collected from the jugular vein and allowed to
sit so that it would coagulate. The collected bronchoalveolar
lavage ﬂuid (BALF) and coagulated blood were, respectively,
centrifugedat630gfor7minandat3700gfor10minat4◦C,
respectively. After centrifugation, the supernatants of BALF
and serum were stored at −20
◦C until the determinations
of cytokines, including interleukin (IL)-2, IL-4, IL-5, tumor
necrosis factor (TNF)-α and interferon (IFN)-γ by ﬂow
cytometric methods [33] using mouse Th1/Th2 cytokine
CBA kits, of total immunoglobulin E (IgE), and of total
IgG2a using enzyme-linked immunosorbent assay (ELISA)
kits (Pharmingen, San Diego, CA, USA) according to the
respective recommendations of the manufacturer. OVA-
speciﬁc IgE was measured as described previously [34]
with some modiﬁcations. Wells were coated with 100μL
of OVA (20μg/mL) instead of the capture antibody. Levels
are expressed in arbitrary units, where one arbitrary unit
equalstheopticaldensityofthesampledividedbytheoptical
density of unchallenged mouse serum or BALF (standard).
The pellet from BALF wasre-suspended in ACK lysing buﬀer
(1.658g NH4Cl, 0.2g KHCO3 and 1.44mg EDTA in 200mL4 Evidence-Based Complementary and Alternative Medicine
of water) to lyse the residual erythrocytes in each sample.
The number of inﬂammatory cells was counted using a
hemocytometer (Hausser Scientiﬁc, Horsham, PA, USA).
Cytospun slides were stained and diﬀerentiated in a blinded
fashion by counting at least 100 cells under light microscopy.
2.5. Xylazine/Ketamine-Induced Anesthesia. According to the
method described by Robichaud et al. [35] and modiﬁed
by us, S-petasin (10–100μmol/kg, s.c.) or rolipram (0.01–
1μmol/kg, s.c.), a reference drug, was injected into 8–
12 week-old female BALB/c mice 1h or 15min, respec-
tively, prior to an i.p. injection of xylazine (10mg/kg)/
ketamine (70mg/kg). The vehicle (control) for S-petasin
or for rolipram was a mixture of alcohol:DMSO:30%
HPβCD:saline(0.5:0.5:1:8,v/v),oralcohol:DMSO:PEG
400:saline (0.5:0.5:1:8, v/v), respectively. After loss of the
righting reﬂex (i.e., when a mouse remained on its back and
no longer spontaneously righted itself to a prone position),
the duration of anesthesia was measured until its return as
an endpoint [35].
2.6. OVA-Induced Tracheal Contractions In Vitro. Male Hart-
ley guinea pigs (500–600g) were sensitized by intramuscular
injections of 0.7mL of 5% (w/v) OVA in saline on Days
1, 4 and 43, and in adjuvant on Days 25 and 39 into each
thigh, according to a method described by Underwood et al.
[19] and modiﬁed by us. Three days after the last injection,
sensitized guinea pigs were sacriﬁced by cervical dislocation,
and their tracheas removed. Each trachea was cut into six
segments. Each segment consisted of three cartilage rings.
All segments were cut open opposite the trachealis. After the
segments were randomized to minimize regional variability,
they were tied at one end to holders via silk sutures, placed
in 5mL of normal Krebs solution containing indomethacin
(3μM), gassed with a mixture of 95% O2 plus 5% CO2 at
37
◦C, and attached by the other end of each segment to
force displacement transducers (Grass FT03, Quincy, MA,
USA) for the isometric recording of tension changes on
a polygraph (Gould RS3200, Cleveland, OH, USA). The
composition of the normal Krebs solution was (mM): NaCl
118, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, CaCl2 2.5, NaHCO3
25 and dextrose 10.1. Tissues were suspended in normal
Krebssolutionunderaninitialtensionof1.5gandallowedto
equilibrate for at least 1h with washing at 15-min intervals.
After the tissues were precontracted with KCl (60mM) and
washed with normal Krebs solution, OVA (0.1–100μg/mL)
was cumulatively added, and contractions were allowed to
reach a steady state at each concentration. To evaluate the
suppressiveeﬀectofS-petasinonOVA-inducedcontractions,
each tissue was preincubated with each concentration (30–
300μM) of S-petasin or its vehicle for 15min and then
challenged with cumulative OVA again. Therefore, the log
concentration-response curves of OVA were constructed in
the absence and presence of S-petasin. The tension of the
precontraction induced by KCl was set as 100%.
2.7. Statistical Analysis. Concentrations of test compounds
at which 50% of maximum activity (IC50 or EC50 value)
w a sp r o d u c e dw e r ec o m p a r e dt oe a c ho t h e r .T h eI C 50 and
EC50 values were calculated using a non-linear regression
analysis by the software SigmaPlot 10.0 (Sigma Chemical, St.
Louis, MO, USA). All values are given as the mean ± SEM.
Diﬀerencesamongvalueswerestatisticallycalculatedbyone-
way analysis of variance (ANOVA), and then determined by
Dunnett’s test. The diﬀerence between two values, however,
was determined by use of student’s t-test. Diﬀerences with
P<. 05 were considered statistically signiﬁcant.
3. Results
3.1.SelectiveandCompetitiveInhibitionofPDE4byS-Petasin.
S-Petasin (1–100μM) concentration-dependently inhibited
PDE3 (Figure 2(a))a n dP D E 4( Figure 2(b))w i t hI C 50 values
of 25.5 ± 1.5μM( n = 4) and 17.5 ± 2.4μM( n = 6),
respectively, which signiﬁcantly diﬀered from each other
(Table 1). Figure 2(c) shows the concentration-inhibition
curve of milrinone, a selective PDE3 inhibitor, on PDE3,
and Figure 2(d) shows that of Ro 20-1724, a selective
PDE4 inhibitor, on PDE4. However, S-petasin did not
inhibit PDE1, PDE2 or PDE5 activities (IC50 values >
100μM, Table 1). The IC50 values of all reference drugs
used are shown in Table 1. According to the Lineweaver-
Burk analysis, S-petasin (3–30μM) and milrinone (0.3–
3μM) competitively inhibited PDE3 activity (Figures 3(a)
and 3(b)), because the 1/Vmax values were not signiﬁcantly
aﬀected by various concentrations of S-petasin or milrinone.
Their Ki values were, respectively, calculated to be 25.3 ± 2.0
(n = 4) and 1.6 ± 0.2 (n = 4) μM (Figures 3(a) and 3(b),
inset). Similarly, S-petasin (3–30μM) and Ro 20-1724 (1–
10μM) competitively inhibited PDE4 activity (Figures 3(c)
and 3(d)). Their Ki values were, respectively, calculated to
be 18.1 ± 1.7μM( n = 4) and 4.2 ± 0.7μM( n = 4) (Figures
3(c) and 3(d), inset). The Ki value of S-petasin for PDE3
signiﬁcantly diﬀered from that for PDE4, suggesting that S-
petasin has a higher aﬃnity for PDE4 than for PDE3. The
Ki values of S-petasin and their reference drugs are shown
in Table 1. The anti-inﬂammatory eﬀects of PDE4 inhibitors
were reported to be associated with inhibition of PDE4
catalyticactivity[36],andtheanti-inﬂammatoryeﬀectswere
also correlated to PDE4L inhibition [30]. Therefore, the
IC50 values (Table 1)o fS-petasin (17.5μM) and Ro 20-1724
(6.9μM) for inhibiting PDE4 catalytic activity were taken to
be the PDE4L values.
3.2. PDE4H/PDE4L Ratios. S-Petasin (3–300μM) concen-
tration-dependently displaced the [3H]-rolipram binding on
HARBSsofguineapigbraincellmembranes(Figure 4(a)).At
the highest concentration (300μM), however, the percentage
displacement by S-petasin was 28.0% ±5.7% (n = 7). Owing
to the solubility of S-petasin, its concentration cannot exceed
300μM. In other words, the EC50 value of S-petasin for
the displacement was >300μM. Ro 20-1724 (1–10000nM),
a selective PDE4 inhibitor, also concentration-dependently
displaced [3H]-rolipram binding on HARBSs (Figure 4(b)).
In contrast to S-petasin, the percentage of the displacement
by Ro 20-1724 at the highest concentration (10000nM) was
100% ± 2.1% (n = 9). The EC50 value of Ro 20-1724 forEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Log concentration-inhibition curves of S-petasin and its reference drugs on phosphodiesterase 3 (PDE3) and PDE4 activities. S-
Petasin (a, b), milrinone, a selective PDE3 inhibitor (c), and Ro 20-1724, a selective PDE4 inhibitor (d) concentration-dependently inhibited
PDE3 (a, c) and PDE4 (b, d) activities. Each value represents the mean ± SEM (n = 4–8).
displacement was 95.8 ± 13.6nM (n = 9). According to the
deﬁnition (see Section 2), the PDE4H values of S-petasin and
Ro 20-1724 were >300μM and 95.8 ± 13.6nM, respectively.
Thus, the PDE4H/PDE4L values of S-petasin and Ro 20-1724
were calculated to be >17 and 0.014, respectively.
3.3. Suppression of AHR In Vivo. Penh values at the baseline
for control (vehicle), non-challenged and 10 and 30μmol/kg
S-petasin subcutaneously injected groups were 3.04 ± 0.31,
2.95 ± 0.31, 3.19 ± 0.47 and 3.13 ± 0.32, respectively,
and these values did not signiﬁcantly diﬀer from each
other. Penh values of PBS nebulization for each group were
2.87 ± 0.12, 2.82 ± 0.06, 2.99 ± 0.22 and 3.02 ± 0.23,
respectively, which also did not signiﬁcantly diﬀer from each
other. Administration of nebulized PBS did not aﬀect the
Penh value of the baseline in each group. However, MCh6 Evidence-Based Complementary and Alternative Medicine
Table 1: The IC50 and Ki (μM) values of S-petasin and reference drugs on PDE isozymes 1–5.
Test compound PDE isozyme
123 4 5
S-Petasin
IC50 >100 (n = 3) >100 (n = 3) 25.5 ± 1.5 (n = 4) 17.5 ± 2.4 (n = 6)∗ >100 (n = 3)
Ki ND ND 25.3 ± 2.0 (n = 4) 18.1 ± 1.7 (n = 4)∗ ND
Reference drugsa
IC50 36.5 ± 8.8 (n = 4) 6.5 ± 1.0 (n = 4) 1.5 ± 0.2 (n = 8) 6.9 ± 0.6 (n = 4) 4.1 ± 1.1 (n = 4)
Ki ND ND 1.6 ± 0.2 (n = 4) 4.2 ± 0.7 (n = 4) ND
All values are expressed as the mean ± SEM (n), and n is the number of experiments. ND, not determined.
aReference drugs for PDE isozymes 1, 2, 3, 4 and 5 were vinpocetin, EHNA, milrinone, Ro 20-1724 and zaprinast, respectively.
∗P<. 05, compared to the corresponding value of PDE3.
(6.25–50mg/mL) concentration-dependently increased Penh
values from 1.08 ± 0.08-fold of PBS exposure to 1.67 ± 0.07-
fold in control sensitized and challenged mice (Figure 5(a)).
S-Petasin (10–30μmol/kg, s.c.) dose-dependently and signif-
icantlyattenuatedtheenhancementofthePenh valueinduced
by MCh at 50mg/mL. The Penh value of MCh (50mg/mL)
in non-challenged mice was almost unchanged compared to
that of PBS nebulization and was signiﬁcantly less than that
in control sensitized and challenged mice (Figure 5(a)).
3.4. Suppression of Inﬂammatory Cells in BALF. Total in-
ﬂammatory cells, macrophages, lymphocytes, neutrophils
and eosinophils from the BALF of control sensitized
and challenged mice signiﬁcantly increased compared to
non-challenged mice (Figure 5(b)). S-Petasin (10–30μmol/
kg, s.c.) also signiﬁcantly suppressed the increases in
total inﬂammatory cells, lymphocytes, neutrophils and
eosinophils,withtheexceptionoflymphocytesat10μmol/kg
(Figure 5(b)). Unexpectedly, macrophages were not aﬀected
by S-petasin treatment.
3.5. Suppression of Cytokines in BALF. Compared to non-
challenged mice, the levels of cytokines, such as IL-2, IL-4,
IL-5, IFN-γ and TNF-α in the BALF of control sensitized
and challenged mice signiﬁcantly increased (Figure 5(c)). S-
Petasin (10–30μmol/kg, s.c.) also signiﬁcantly suppressed
increases in the levels of these cytokines, with the exception
of IL-4 at a dose of 10μmol/kg (Figure 5(c)).
3.6. Eﬀects on IgG2a and IgE in the Serum and BALF.
Compared to non-challenged mice, the total IgG2a levels in
the serum of control sensitized and challenged mice were
signiﬁcantly reduced. S-Petasin (30μmol/kg, s.c.) signiﬁ-
cantly reversed this reduction (Figure 6(a)). Levels of total
and OVA-speciﬁc IgE in the serum and BALF of control
sensitized and challenged mice were signiﬁcantly enhanced
compared to non-challenged mice (Figures 6(b)–6(e)). S-
Petasin (10–30μmol/kg, s.c.) dose-dependently and signiﬁ-
cantly suppressed these enhancements with the exception of
total IgE in the BALF at 10μmol/kg.
3.7. No Eﬀect on Xylazine/Ketamine-Induced Anesthesia. The
durations of xylazine/ketamine-induced anesthesia in con-
trol (vehicle) mice of S-petasin- and rolipram-treated group
were 20.6 ± 2.2 (n = 10) and 22.8 ± 2.7min (n = 11), respec-
tively. Rolipram (0.1–1μmol/kg, s.c.) dose-dependently and
signiﬁcantly shortened the duration (Figure 7(a)). In con-
trast to rolipram, S-petasin (10–100μmol/kg, s.c.) did not
aﬀect the duration (Figure 7(b)).
3.8. Inhibition of OVA-Induced Contractions In Vitro. In
isolated sensitized guinea pig trachea, 60mM KCl evoked
a contraction and increased tension to 997 ± 93mg (n =
36), which was set as 100%. OVA (0.01–100μg/mL) alone
concentration-dependently enhanced the tension from the
baseline to 130.8 ± 11.6% (n = 9) of the 60mM KCl-
induced contractions (Figure 8(a)). The log concentration-
response curve of OVA was unaltered by 1μM nifedipine,
a selective voltage-dependent calcium channel blocker [37]
(data not shown). S-Petasin (30–100μM) also did not
signiﬁcantly inhibit OVA (100μg/mL)-induced contractions
compared to the control (vehicle), although S-petasin at
300μM did (Figure 8(a)). The vehicle of S-petasin did not
aﬀect the baseline tension or OVA (100μg/mL)-induced
maximal contractions (data not shown). However, S-petasin
(30–300μM) concentration-dependently and signiﬁcantly
relaxed the baseline tension (Figure 8(b)). In contrast, Ro
20-1724 (10–30μM) concentration-dependently inhibited
OVA (10–100μg/mL)-induced contractions. Ro 20-1724
at 30μM even signiﬁcantly inhibited OVA (10μg/mL)-
induced contractions (Figure 8(c)). Similarly to S-petasin,
Ro 20-1724 (3–30μM) concentration-dependently and sig-
niﬁcantly relaxed the baseline tension (Figure 8(d)).
4. Discussion
In the present results, S-petasin suppressed all types of
inﬂammatory cells examined, including total inﬂammatory
cells, lymphocytes, neutrophils and eosinophils, but not
macrophages, in the BALF of sensitized and challenged mice.
The reason that macrophages were unaﬀected by S-petasin
is unclear. Allergic asthma is a chronic respiratory disease
characterized by AHR, mucus hypersecretion, bronchial
inﬂammation and elevated IgE levels. T-helper type 2
(Th2) cells, together with other inﬂammatory cells such
as eosinophils, B cells and mast cells, have been proposed
as playing critical roles in the initiation, development andEvidence-Based Complementary and Alternative Medicine 7
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chronicity of this disease [38]. One hypothesis emphasizes
an imbalance in Th cell populations favoring expression of
Th2 over Th1 cells. Cytokines released from Th2 cells are
IL-4, -5, -6, -9 and -13, and those from Th1 cells are IL-2
and -12, IFN-γ and TNF-α [39, 40]. In the present results,
S-petasin suppressed levels of IL-2, -4 and -5, IFN-γ and
TNF-α, suggesting that S-petasin suppresses both Th1 and
Th2 cells. This inhibitory eﬀect of S-petasin on both Th18 Evidence-Based Complementary and Alternative Medicine
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and Th2 cells is similar to that of AWD 12-281, a selective
PDE4 inhibitor [41]. Th1 and Th2 cells have, respectively,
been implicated in autoimmune and atopic diseases [42].
Therefore AWD 12-281 is currently under clinical evaluation
for the topical treatment of atopic dermatitis [41].
IL-4 and -13 have been shown to induce AHR in mouse
asthma models [43, 44]. IL-4 has three primary eﬀects.
First, IL-4 promotes B cell diﬀerentiation to plasma cells
that secrete antigen-speciﬁc IgE antibodies. Second, IL-
4 promotes mast cell proliferation. Third, increased IL-4
upregulatesendothelialcellexpressionofadhesionmolecules
foreosinophils[45].IL-5mobilizesandactivateseosinophils,
leading to the release of a major basic protein, cysteinyl-
leukotrienes, and eosinophil peroxidase that contribute to
tissue damage and AHR [44, 46]. Phosphoinositide 3-
kinase δ (p110δ) was shown to play a crucial role in the
development, diﬀerentiation and antigen receptor-induced
proliferation of mature B cells [47, 48], and inhibition of
p110δ attenuates allergic airway inﬂammation and AHR in
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a murine asthma model [48, 49]. In addition, IL-4 and
-13 are important in directing B cell growth, diﬀerentia-
tion and secretion of IgE [50]. However, IFN-γ released
from Th1 cells preferentially directs B cell switching of
IgM to IgG2a and IgG3 in mice [51, 52]. The biological
activities of IgE are mediated through the high-aﬃnity IgE
receptor (FcεRI) on mast cells and basophils. Cross-linking
of the FcεRI initiates multiple signaling cascades leading
to cellular degranulation and activation [53, 54]. Recently,
p110δ activity was reported to be critical for allergen-IgE-
induced mast cell degranulation and release of cytokines
[55].Inhibitionofp110δ thereforeattenuatestheproduction
of IgE as well as allergen-IgE-induced mast cell activation
during allergic inﬂammation. The calcium channels in mast
cell membranes were proposed to diﬀer from those in
cardiovascular tissues [56], which are sensitive to nifedipine.
In the present in vitro results, S-petasin (30–100μM), but
n o ta t3 0 0μM which is beyond a physiological condition, did
not inhibit cumulative OVA-induced contractions of isolated
sensitized guinea pig trachealis, which were unaﬀected by
1μM nifedipine, suggesting that S-petasin does not inhibit
degranulation or activation of mast cells [57]. Indeed, S-
petasin was reported to be an L-type voltage-dependent Ca2+
channelblockerinrataorticsmoothmusclecells[58,59]and
in mouse NG 108-15 neuronal cells [60]. In these neuronal
cells, a higher concentration (100μM) of S-petasin was also
reported to inhibit the delayed rectiﬁer K+ current in a
time-dependent manner, suggesting that such a blockage
does not seem to be instantaneous, but develops with time
after the channels are opened [60] .T h eb l o c k a g eb yS-
petasin may contribute to the regulation of neuronal activity,
but not to relaxation of the trachea-bronchial tree. Owing
to the diﬀerent sensitivities between vascular and tracheal
smooth muscle cells, we demonstrated that in the presence
of nifedipine (10μM), S-petasin or S-isopetasin (100μM
each) further relaxed the CCh-induced precontractions in
isolated guinea pig trachealis via cAMP-PDE inhibition
or antimuscarinic eﬀects, respectively [11]. The extents of
relaxation by nifedipine and these two sesquiterpenes (S-
petasin and S-isopetasin) were 20%–30%, and 70%–80%,
respectively. In other words, there are two mechanisms, at
least, in tracheal relaxation by S-petasin or S-isopetasin. In
the present results, S-petasin and Ro 20-1724 concentration-
dependently relaxed the baseline in isolated sensitized guinea
pig trachealis, suggesting that S-petasin has a bronchodila-
tory eﬀect. This aspect is strongly supported by our previous
reports [9, 11]. In addition, S-petasin dose-dependently and
signiﬁcantly suppressed total and OVA-speciﬁc IgE levels in
the serum and BALF, and enhanced the level of total IgG2a in
the serum of sensitized and challenged mice, suggesting that
S-petasin appears to have immunoregulatory eﬀects.
Selective PDE4 inhibitors speciﬁcally prevent the hydrol-
ysis of cAMP, a 3 ,5 -cyclic nucleotide, and therefore
have broad anti-inﬂammatory eﬀects such as inhibition of
cell traﬃcking, and cytokine and chemokine release from
inﬂammatory cells. The second-generation PDE4 inhibitors,
cilomilast and roﬂumilast, have reached the clinical trial
stage and have exhibited some beneﬁcial eﬀects in treating
asthma and COPD [61]. The eﬀectiveness of these PDE4
inhibitors may be limited by their clinical potency when
using doses that have minimal adverse eﬀects on headaches,
diarrhea, nausea and abdominal pain. The PDE4H/PDE4L
ratios of cilomilast and roﬂumilast were reported to be 1
[62]a n d3[ 29], respectively, which are considerably greaterEvidence-Based Complementary and Alternative Medicine 11
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Figure 8: Eﬀects of S-petasin (a, b) and Ro 20-1724 (c, d) on cumulative OVA-induced contractions (a, c) and baseline tension (b, d) in
isolated sensitized guinea pig trachealis. ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001, compared to the control (vehicle). Each value represents the
mean ± SEM (n = 5–9).
than that (0.01–0.001) of rolipram [30]. Owing to its low
PDE4H/PDE4L ratio, cilomilast was discontinued for use
against asthma after phase II clinical trials in 2003 [61]. In
terms of tolerability over 6 months with 15 mg twice daily
for COPD in a phase III study, cilomilast was reported to
be associated with higher frequencies of diarrhea and nausea
than a placebo [61]. Roﬂumilast is still being evaluated for
asthma and COPD in phase III clinical trials at present,
and is reported to reduce these adverse eﬀects after longer-
termtreatmentat0.5mgoncedaily[61].ThePDE4H/PDE4L
ratio of AWD 12-281, another selective PDE4 inhibitor, was
calculated to be approximately 11 [63]. AWD 12-281 has
been undergoing clinical development phase IIa trials for
COPD, and has been reported to be a unique potential drug
forthetopicaltreatmentofasthmaandCOPD[64].Recently,
AWD 12-281 was reported to be a very promising drug
candidate for treating lung inﬂammation when administered
by inhalation and for treating atopic dermatitis [65].
In the present results, the PDE4H value of S-petasin was
>300μM, suggesting that it has a low aﬃnity for HARBSs
of brain cell membranes. Thus the PDE4H/PDE4L ratio of
S-petasin was >17, which is greater than that of AWD 12-
281. In addition, S-petasin did not aﬀect xylazine/ketamine-
induced anesthesia. This result is consistent with its low
aﬃnity for HARBSs of brain cell membranes. However,
rolipram, a selective PDE4 inhibitor, reversed the anes-
thesia. The reversing eﬀect may occur through presy-
naptic α2-adrenoceptor inhibition [66], because MK-192,12 Evidence-Based Complementary and Alternative Medicine
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Figure 9: Mechanisms of action of S-petasin. S-Petasin mainly inhibits PDE3/4 activities and results in increase of cAMP, which activates
cAMP-dependentproteinkinase(PKA)andincreasescalciumextrusionfromintracellularspaceanduptaketosarcoplasmicreticula(SR).S-
Petasin was also reported to inhibit voltage-dependent calcium channels (VDCCs). Therefore, S-petasin largely decreases the concentration
ofintracellularcalcium([Ca2+]i)andresultsintrachea-bronchialsmoothmusclerelaxation.TheincreasedcAMPalsohasanti-inﬂammatory
and immunoregulatory eﬀects. AC, adenylate cyclase. Up and down arrows indicate increases and decreases, respectively.
an α2-adrenoceptor antagonist, was reported to reverse
xylazine/ketamine-induced anesthesia in rats [67] and trig-
ger vomiting in ferrets [66]. In contrast, clonidine, an α2-
adrenoceptor agonist, prevented emesis induced by PDE4
inhibitors in ferrets [66]. In contrastto rolipram or AWD 12-
281, S-petasin is a dual PDE3/4 inhibitor. Thus, the present
results for S-petasin at least partially explain why Petasites
formosanus is used as a folk medicine to treat asthma in
Taiwan.However,whetherS-petasinhasotheradverseeﬀects
or has good bioavailability after oral administration should
be further evaluated. In summary, PDE3/4 inhibition and
VDCC blockage are the main mechanisms of action of S-
petasin (Figure 9).
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